Lieming Ding

1.9k total citations
53 papers, 616 citations indexed

About

Lieming Ding is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Lieming Ding has authored 53 papers receiving a total of 616 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 34 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Lieming Ding's work include Lung Cancer Treatments and Mutations (29 papers), Lung Cancer Research Studies (14 papers) and Colorectal Cancer Treatments and Studies (9 papers). Lieming Ding is often cited by papers focused on Lung Cancer Treatments and Mutations (29 papers), Lung Cancer Research Studies (14 papers) and Colorectal Cancer Treatments and Studies (9 papers). Lieming Ding collaborates with scholars based in China, United States and Spain. Lieming Ding's co-authors include Fenlai Tan, Yinxiang Wang, Guojian Xie, Yanping Wang, Wei He, Dechang Wang, Xiaodong Zhang, Xiaobin Yuan, Xiaoyan Shen and Bin Wu and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Lieming Ding

51 papers receiving 607 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lieming Ding China 13 369 325 194 79 48 53 616
Maria Anna Bareschino Italy 16 381 1.0× 382 1.2× 297 1.5× 51 0.6× 33 0.7× 27 707
Youwei Bi United States 14 307 0.8× 275 0.8× 225 1.2× 32 0.4× 36 0.8× 25 768
Oliver Boix Germany 11 233 0.6× 499 1.5× 227 1.2× 29 0.4× 47 1.0× 20 749
Assunta Sgambato Italy 15 416 1.1× 441 1.4× 293 1.5× 39 0.5× 25 0.5× 31 742
Paola Claudia Sacco Italy 18 438 1.2× 505 1.6× 340 1.8× 51 0.6× 43 0.9× 42 889
Francesca Casaluce Italy 15 462 1.3× 512 1.6× 326 1.7× 45 0.6× 31 0.6× 38 841
Joseph Chen United States 13 527 1.4× 452 1.4× 240 1.2× 30 0.4× 39 0.8× 27 801
Caterina Fontanella Italy 13 196 0.5× 375 1.2× 145 0.7× 51 0.6× 53 1.1× 43 625
Yasuhito Fujisaka Japan 17 272 0.7× 481 1.5× 247 1.3× 26 0.3× 33 0.7× 51 885
Ling Gao United States 15 317 0.9× 343 1.1× 207 1.1× 18 0.2× 55 1.1× 46 633

Countries citing papers authored by Lieming Ding

Since Specialization
Citations

This map shows the geographic impact of Lieming Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lieming Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lieming Ding more than expected).

Fields of papers citing papers by Lieming Ding

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lieming Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lieming Ding. The network helps show where Lieming Ding may publish in the future.

Co-authorship network of co-authors of Lieming Ding

This figure shows the co-authorship network connecting the top 25 collaborators of Lieming Ding. A scholar is included among the top collaborators of Lieming Ding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lieming Ding. Lieming Ding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Jie, Zhehai Wang, Yao Yu, et al.. (2024). Efficacy and safety of MCLA-129, an EGFR/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8604–8604. 5 indexed citations
2.
Lü, Fang, Xiaoxin Li, Hong Dai, et al.. (2023). Safety and tolerability of oral vorolanib for neovascular (wet) age-related macular degeneration: a phase I, open-label study. Eye. 37(15). 3228–3233. 4 indexed citations
3.
Han, Han, Xiaofeng Yang, Ying Zhao, et al.. (2023). Abstract 504: BPI-472372: a potent and orally bioavailable small molecule inhibitor of CD73 for cancer immunotherapy. Cancer Research. 83(7_Supplement). 504–504. 1 indexed citations
4.
5.
6.
7.
Li, Hua, et al.. (2022). Simultaneous quantitation of befotertinib (D-0316) and its metabolite D-0865 in human plasma by LC-MS/MS method. Journal of Chromatography B. 1214. 123499–123499. 2 indexed citations
8.
Liang, Chris, et al.. (2022). Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity. Molecular Therapy — Oncolytics. 24. 577–584. 19 indexed citations
9.
Ma, Yuxiang, Yu Liu, Yang Zhang, et al.. (2022). Ensartinib in advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, two-staged, phase 1 trial. Journal of Thoracic Disease. 14(12). 4751–4762. 10 indexed citations
10.
11.
Liu, Lei, Cheng Huang, Hongsheng Liu, et al.. (2021). Transcriptomic and Mutational Analysis Discovering Distinct Molecular Characteristics Among Chinese Thymic Epithelial Tumor Patients. Frontiers in Oncology. 11. 647512–647512. 6 indexed citations
12.
Song, Yan, Jinwan Wang, Xiubao Ren, et al.. (2021). Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chinese Journal of Cancer Research. 33(1). 103–114. 3 indexed citations
13.
Yue, Dongsheng, Weiran Liu, Liuwei Gao, et al.. (2021). Integrated Multiomics Analyses Revealing Different Molecular Profiles Between Early- and Late-Stage Lung Adenocarcinoma. Frontiers in Oncology. 11. 746943–746943. 7 indexed citations
14.
Zhou, Sufeng, Wei Liu, Chen Zhou, et al.. (2020). Mass balance, metabolic disposition, and pharmacokinetics of [14C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects following oral administration. Cancer Chemotherapy and Pharmacology. 86(6). 719–730. 1 indexed citations
15.
Zhang, Panpan, Shaolei Li, Chao Lv, et al.. (2018). BPI-9016M, a c-Met inhibitor, suppresses tumor cell growth, migration and invasion of lung adenocarcinoma via miR203-DKK1. Theranostics. 8(21). 5890–5902. 30 indexed citations
16.
Tan, Fenlai, Yanping Wang, Haibo Chen, et al.. (2017). Icotinib inhibits EGFR signaling and alleviates psoriasis-like symptoms in animal models. Biomedicine & Pharmacotherapy. 98. 399–405. 8 indexed citations
17.
18.
Hu, Xingsheng, Baohui Han, Aiqin Gu, et al.. (2014). A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC). Lung Cancer. 86(2). 207–212. 31 indexed citations
19.
20.
Hu, Shaojing, Guojian Xie, Charles B. Davis, et al.. (2012). Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors. Bioorganic & Medicinal Chemistry Letters. 22(19). 6301–6305. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maria Anna Bareschino Breakdown of academic impact, for papers by Youwei Bi Breakdown of academic impact, for papers by Oliver Boix Breakdown of academic impact, for papers by Assunta Sgambato Breakdown of academic impact, for papers by Paola Claudia Sacco Breakdown of academic impact, for papers by Francesca Casaluce Breakdown of academic impact, for papers by Joseph Chen Breakdown of academic impact, for papers by Caterina Fontanella Breakdown of academic impact, for papers by Yasuhito Fujisaka Breakdown of academic impact, for papers by Ling Gao
Rankless by CCL
2026